ArticleHepatology international2014
Evaluation and comparison of microvessel density using the markers CD34 and CD105 in regenerative nodules, dysplastic nodules and hepatocellular carcinoma.
Article in Hepatology international, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 16 citations in OpenAlex.
- Current Concepts of Precancerous Lesions of Hepatocellular Carcinoma: Recent Progress in Diagnosis.Diagnostics (Basel, Switzerland) · 2023Review
- CD105: tumor diagnosis, prognostic marker and future tumor therapeutic target.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022Review
- Heterogeneity of Blood Vessels and Assessment of Microvessel Density-MVD in Gingivitis.Journal of clinical medicine · 2022Article
- Comparison of superb microvascular imaging (SMI) quantified with ImageJ to quantified contrast-enhanced ultrasound (qCEUS) in liver metastases-a pilot study.Quantitative imaging in medicine and surgery · 2022Article
- The Role of Endoglin in Hepatocellular Carcinoma.International journal of molecular sciences · 2021Review
- Heterogeneity of antigenic constellation in human hepatocellular carcinoma.Experimental and therapeutic medicine · 2021Article
- High expression of endothelial progenitor cell-induced angiogenic markers is associated with bile acid levels in HCC.Oncology letters · 2020Article
- Sorafenib and Mesenchymal Stem Cell Therapy: A Promising Approach for Treatment of HCC.Evidence-based complementary and alternative medicine : eCAM · 2020Article
- Role of Endoglin (CD105) in the Progression of Hepatocellular Carcinoma and Anti-Angiogenic Therapy.International journal of molecular sciences · 2018Review
- Quantitative evaluation of microvessel density using CD34 in clinical variants of ameloblastoma: An immunohistochemical study.Journal of oral and maxillofacial pathology : JOMFPArticle
- Impact of CD34-dependent Micro Vessel Density on Periapical Odontogenic Cysts.Cancer diagnosis & prognosisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe progression of hepatocellular carcinoma (HCC) is multifactorial and angiogenesis plays a fundamental role, mainly because HCC is a highly vascularized tumor.
methodsIn this study, we determined microvessel density (MVD) using the immunohistochemical markers, CD34 and CD105 (Endoglin), in 44 hepatectomy specimens, encompassing 44 malignant nodules (HCC), 44 regenerative nodules (RN), and 15 dysplastic nodules (DN). The evaluation included the determination of MVD in all nodules. For statistical analysis, a descriptive analysis was carried out using measurements of position and dispersion for continuous variables; ANOVA was used to compare between groups, considering p < 0.05 as statistically significant.
resultsWe observed a significant difference when comparing CD34 and CD105 immunoexpression in HCC, DN, and RN. CD105 was predominantly expressed in the peripheral regions in HCC, with mean MVD scores of 6.2 ± 4.1 and 10.7 ± 4.4 at the center and periphery of the nodules, respectively, with significant differences between groups (p < 0.0001). CD34 had higher mean MVD scores than CD105 in HCC, with a more uniform positivity pattern. CD105 immunoexpression in DN exhibited a pattern similar to HCC. However, in RN, CD105 exhibited a higher MVD score in the central portion of the nodules. CD105 was expressed in a subset of newly formed microvessels in HCC and demonstrated an elevated mean MVD in cirrhotic or regenerative nodules.
conclusionsMVD determined by CD34 and CD105 expression may be used as an additional parameter to distinguish benign from malignant liver nodules.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.